Medicus Pharma (MDCX) Cash & Equivalents (2023 - 2025)

Medicus Pharma has reported Cash & Equivalents for 3 years, with the latest figure at $8.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 109.04% year-over-year to $8.7 million; the trailing twelve-month figure through Dec 2025 stood at $8.7 million (up 109.04% YoY), and the FY2025 full-year result was $8.7 million, up 109.04% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $8.7 million, roughly flat from $8.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $9.7 million in Q2 2025, with the low at $1.7 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $6.2 million across 3 years, with a median of $6.4 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 142.21% — and 2025, when it soared 109.04%.
• Medicus Pharma's Cash & Equivalents stood at $1.7 million in 2023, then surged by 142.21% to $4.2 million in 2024, then soared by 109.04% to $8.7 million in 2025.
• The last three Cash & Equivalents figures came in at $8.7 million (Q4 2025), $8.7 million (Q3 2025), and $9.7 million (Q2 2025), per Business Quant data.